188 related articles for article (PubMed ID: 12493166)
21. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens' antibacterial susceptibility.
Niki Y; Hanaki H; Matsumoto T; Yagisawa M; Kohno S; Aoki N; Watanabe A; Sato J; Hattori R; Terada M; Koashi N; Kozuki T; Maruo A; Morita K; Ogasawara K; Takahashi Y; Watanabe J; Takeuchi K; Fujimura S; Takeda H; Ikeda H; Sato N; Niitsuma K; Saito M; Koshiba S; Kaneko M; Miki M; Nakanowatari S; Honda Y; Chiba J; Takahashi H; Utagawa M; Kondo T; Kawana A; Konosaki H; Aoki Y; Ueda H; Sugiura H; Ichioka M; Goto H; Kurai D; Okazaki M; Yoshida K; Yoshida T; Tanabe Y; Kobayashi S; Okada M; Tsukada H; Imai Y; Honma Y; Nishikawa K; Yamamoto T; Kawai A; Kashiwabara T; Takesue Y; Wada Y; Nakajima K; Miyara T; Toda H; Mitsuno N; Sugimura H; Yoshioka S; Kurokawa M; Munekawa Y; Nakajima H; Kubo S; Ohta Y; Mikasa K; Maeda K; Kasahara K; Koizumi A; Sano R; Yagi S; Takaya M; Kurokawa Y; Kusano N; Mihara E; Kuwabara M; Fujiue Y; Ishimaru T; Matsubara N; Kawasaki Y; Tokuyasu H; Masui K; Negayama K; Ueda N; Ishimaru M; Nakanishi Y; Fujita M; Honda J; Kadota J; Hiramatsu K; Aoki Y; Nagasawa Z; Suga M; Muranaka H; Yanagihara K; Fujita J; Tateyama M; Sunakawa K; Totsuka K
J Infect Chemother; 2009 Jun; 15(3):156-67. PubMed ID: 19554400
[TBL] [Abstract][Full Text] [Related]
22. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
23. Emerging resistance problems among respiratory tract pathogens.
Lister PD
Am J Manag Care; 2000 May; 6(8 Suppl):S409-18. PubMed ID: 10977480
[TBL] [Abstract][Full Text] [Related]
24. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
Bhavnani SM; Andes DR
Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
[TBL] [Abstract][Full Text] [Related]
25. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
Lopez H; Stepanik D; Vilches V; Scarano S; Sarachian B; Mikaelian G; Finlay J; Sucari A
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).
Deshpande LM; Jones RN
Diagn Microbiol Infect Dis; 2000 Jun; 37(2):139-42. PubMed ID: 10863108
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
[TBL] [Abstract][Full Text] [Related]
28. [In vitro comparative activity of moxifloxacin and other antimicrobials against respiratory pathogens].
Prado V; Giangrieco M; Durán C; Ojeda A; van Flaskamp R
Rev Med Chil; 2000 Dec; 128(12):1319-26. PubMed ID: 11227240
[TBL] [Abstract][Full Text] [Related]
29. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
[TBL] [Abstract][Full Text] [Related]
30. The activity of grepafloxacin against respiratory pathogens in the UK.
Wise R; Andrews JM
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870
[TBL] [Abstract][Full Text] [Related]
31. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of moxifloxacin against local bacterial isolates.
Ling ML; Tan PL
Ann Acad Med Singap; 2001 Nov; 30(6):607-10. PubMed ID: 11817288
[TBL] [Abstract][Full Text] [Related]
33. Activity of temafloxacin and other fluoroquinolones against typical and atypical community-acquired respiratory tract pathogens.
Hardy DJ
Am J Med; 1991 Dec; 91(6A):12S-14S. PubMed ID: 1662881
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.
Dubois J; St -Pierre C
Diagn Microbiol Infect Dis; 2001; 40(1-2):35-40. PubMed ID: 11448561
[TBL] [Abstract][Full Text] [Related]
35. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
Morrissey I; Robbins M; Viljoen L; Brown DF
J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
[TBL] [Abstract][Full Text] [Related]
37. In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY antimicrobial surveillance program (1998-1999).
Bell JM; Turnidge JD; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):315-8. PubMed ID: 12151193
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
[TBL] [Abstract][Full Text] [Related]
39. Microbiological profile of telithromycin, the first ketolide antimicrobial.
Felmingham D
Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of temafloxacin against gram-negative bacteria: an overview.
Hardy DJ
Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
